10x Genomics TXG
$ 16.78
2.76%
Quarterly report 2024-Q3
added 10-29-2024
10x Genomics Balance Sheet 2011-2024 | TXG
Annual Balance Sheet 10x Genomics
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-264 M | -125 M | -505 M | -601 M | -394 M | -35.4 M | -37.3 M | - | - | - | - | - | - |
Long Term Debt |
83.8 M | 86.1 M | 76.8 M | 57 M | 19.8 M | 25.5 M | 6.34 M | - | - | - | - | - | - |
Long Term Debt Current |
11.5 M | 9.04 M | 5.13 M | 5.94 M | 9.88 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 123 M | 312 M | 166 M | - | - | - | - | - | - |
Total Current Liabilities |
127 M | 131 M | 110 M | 118 M | 63 M | - | - | - | - | - | - | - | - |
Total Liabilities |
224 M | 223 M | 201 M | 190 M | 186 M | 344 M | 188 M | - | - | - | - | - | - |
Deferred Revenue |
13.2 M | 7.87 M | 5.34 M | 4.47 M | 4.6 M | 2.78 M | 1.83 M | - | - | - | - | - | - |
Retained Earnings |
-1.28 B | -1.03 B | -863 M | - | -262 M | -231 M | -119 M | - | - | - | - | - | - |
Total Assets |
965 M | 1.03 B | 1.02 B | 929 M | 606 M | 124 M | 75.6 M | - | - | - | - | - | - |
Cash and Cash Equivalents |
359 M | 220 M | 587 M | 664 M | 424 M | 65.1 M | 47.9 M | - | - | - | - | - | - |
Book Value |
741 M | 806 M | 818 M | 739 M | 420 M | -220 M | -113 M | - | - | - | - | - | - |
Total Shareholders Equity |
741 M | 806 M | 818 M | 739 M | 420 M | -220 M | -113 M | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet 10x Genomics
2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
76.5 M | 78.7 M | 81 M | - | - | 92.8 M | 86.1 M | - | 91 M | 93.5 M | 76.8 M | 75.7 M | 65.9 M | 66.3 M | - | - | - | - | 19.8 M | 19.8 M | 19.8 M | 19.8 M | 25.5 M | 25.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
215 M | 206 M | 204 M | - | - | 212 M | 223 M | - | 218 M | 197 M | 201 M | 190 M | 193 M | 202 M | 190 M | 190 M | 190 M | 190 M | 186 M | 186 M | 186 M | 186 M | 101 M | 101 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
17.8 M | 16.4 M | 14.3 M | - | - | 8.53 M | 7.87 M | - | 6.47 M | 5.43 M | 5.34 M | 5.5 M | 5.27 M | 4.48 M | 4.47 M | 4.47 M | 4.47 M | 4.47 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 2.4 M | 2.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-1.42 B | -1.38 B | -1.34 B | - | - | -1.08 B | -1.03 B | - | -970 M | -906 M | -863 M | -845 M | -828 M | -817 M | -805 M | -805 M | -805 M | -805 M | -262 M | -262 M | -262 M | -262 M | -231 M | -231 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
938 M | 930 M | 923 M | - | - | 1.01 B | 1.03 B | - | 1 B | 1 B | 1.02 B | 991 M | 978 M | 954 M | 929 M | 929 M | 929 M | 929 M | 606 M | 606 M | 606 M | 606 M | 124 M | 124 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
398 M | 380 M | 356 M | 315 M | 331 M | 340 M | 227 M | - | 282 M | 320 M | 596 M | 609 M | 649 M | 644 M | 689 M | 689 M | 689 M | 689 M | 424 M | 427 M | 476 M | 476 M | 65.1 M | 65.1 M | - | - | 47.9 M | - | - | - | 41.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
723 M | 724 M | 719 M | - | - | 802 M | 806 M | - | 784 M | 807 M | 818 M | 800 M | 785 M | 752 M | 739 M | 739 M | 739 M | 739 M | 420 M | 420 M | 420 M | 420 M | 23.3 M | 23.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
723 M | 724 M | 719 M | 745 M | 793 M | 802 M | 806 M | - | 784 M | 807 M | 818 M | 800 M | 785 M | 752 M | 739 M | 739 M | 739 M | 739 M | 420 M | 420 M | 420 M | 420 M | -220 M | -220 M | -132 M | -127 M | -113 M | - | - | - | -96.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency